Sangui Biotech International Inc. Announces Earnings Results for the Third Quarter and Nine Months Fiscal Year 2019
May 14, 2019 at 08:42 am
Share
Sangui BioTech International Inc. announced earnings results for the third quarter and sales results for the first nine months fiscal year 2019. For the period, the company achieved revenues from royalty income of USD 63,429. In the same period of the previous year the comparable revenue amounted to USD 65,273. Despite the strong end-of-year business in 2018, royalty income in the first three quarters therefore declined by USD 1,844 or 3% compared to the previous year.
The operating loss for the third quarter of 2019, on the other hand, increased disproportionately by USD 5,352 compared to the previous year to USD 74,150. While royalty income in the first half of the year were still higher than in the previous year, royalty income in the third quarter were USD 2,129 lower than in the same period of the previous year.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
